



# Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)

Yaqin Han<sup>1,2</sup> and Maree T. Smith<sup>1,2\*</sup>

<sup>1</sup> Centre for Integrated Preclinical Drug Development, The University of Queensland, Brisbane, QLD, Australia

<sup>2</sup> School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia

## Edited by:

Susan Hua, The University of Newcastle, Australia

## Reviewed by:

Joel S. Greenberger, University of Pittsburgh Medical Center-Shadyside, USA  
Andreas Bergdahl, Concordia University, Canada

## \*Correspondence:

Maree T. Smith, Centre for Integrated Preclinical Drug Development, The University of Queensland, Level 3, Steele Building, St. Lucia Campus, Brisbane, QLD 4072, Australia  
e-mail: maree.smith@uq.edu.au

Chemotherapy induced peripheral neuropathy (CIPN) is a type of neuropathic pain that is a major dose-limiting side-effect of potentially curative cancer chemotherapy treatment regimens that develops in a “stocking and glove” distribution. When pain is severe, a change to less effective chemotherapy agents may be required, or patients may choose to discontinue treatment. Medications used to alleviate CIPN often lack efficacy and/or have unacceptable side-effects. Hence the unmet medical need for novel analgesics for relief of this painful condition has driven establishment of rodent models of CIPN. New insights on the pathobiology of CIPN gained using these models are discussed in this review. These include mitochondrial dysfunction and oxidative stress that are implicated as key mechanisms in the development of CIPN. Associated structural changes in peripheral nerves include neuronopathy, axonopathy and/or myelinopathy, especially intra-epidermal nerve fiber (IENF) degeneration. In patients with CIPN, loss of heat sensitivity is a hallmark symptom due to preferential damage to myelinated primary afferent sensory nerve fibers in the presence or absence of demyelination. The pathobiology of CIPN is complex as cancer chemotherapy treatment regimens frequently involve drug combinations. Adding to this complexity, there are also subtle differences in the pathobiological consequences of commonly used cancer chemotherapy drugs, viz platinum compounds, taxanes, vincristine, bortezomib, thalidomide and ixabepilone, on peripheral nerves.

**Keywords: chemotherapy-induced peripheral neuropathy (CIPN), mitochondrial dysfunction, oxidative stress, intraepidermal nerve fiber (IENF) degeneration, loss of heat sensitivity**

## INTRODUCTION

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially dose-limiting side effect of many cancer chemotherapy drug treatment regimens (Burton et al., 2007). The prevalence of CIPN varies from 10 to 100% depending upon the particular anticancer drug or drug combination administered, the dosing regimen, the methods of pain assessment and the particular patient situation (Balayssac et al., 2011). The development of CIPN may result in dose reduction of the cancer chemotherapy agents or a switch to less efficacious agents or even cessation of treatment in the extreme (Gutiérrez-Gutiérrez et al., 2010).

Typically, CIPN presents in patients with a “stocking and glove” distribution in the feet and hands, respectively, due to the vulnerability of the long nerves (Boland et al., 2010). Sensory symptoms that are commonly reported include paresthesia, dysesthesia, allodynia, hyperalgesia, hypoalgesia or pain that is burning, shooting or electric-shock-like (Boland et al., 2010). Painful symptoms may persist well beyond discontinuation of treatment (so called “coasting”) (Quasthoff and Hartung, 2002) resulting in a condition as painful or more painful than the original cancer. Furthermore, although slow recovery of peripheral nerve damage may occur in patients with CIPN, this is not always the case and so pain may persist (Peltier and Russell, 2002).

Anticancer drugs that most commonly induce CIPN are platinum compounds (cisplatin and oxaliplatin), spindle

poisons/antitubulins including vincristine and paclitaxel (Wolf et al., 2008; Balayssac et al., 2011), and some newer agents such as the proteasome inhibitor, bortezomib (Hoy, 2013), ixabepilone (Goel et al., 2008) and thalidomide (Kocer et al., 2009). A wide range of solid and hematological malignancies are treated with these compounds and polychemotherapy schedules are used to enhance treatment effectiveness (Cavaletti and Marmiroli, 2010). However, the latter also increase the risk of CIPN (Burton et al., 2007; Argyriou et al., 2013).

The prevalence of cancer is increasing globally with an estimated 17 million new cases projected by 2020 (Kanavos, 2006; Paice, 2011). Cancer survival rates have increased dramatically as new treatments and older therapies are refined to have a greater antitumor effect. This means that the landscape of “cancer pain” has shifted into a form of long term chronic pain in many instances (Burton et al., 2007). In clinical practice, CIPN is poorly diagnosed and under-treated to the detriment of patient quality-of-life and there is no proven method for prevention of CIPN (Balayssac et al., 2011). Although drugs used to provide symptomatic relief of CIPN often lack efficacy and/or have unacceptable side-effects (Balayssac et al., 2005), a recent 5-week randomized, placebo-controlled clinical trial found that oral duloxetine at 60 mg daily produced significant relief of CIPN above placebo (Smith et al., 2013). Despite these promising findings, there is nevertheless a large unmet medical need for novel,

well-tolerated analgesic agents to improve relief of CIPN. In the past decade, new insights on the mechanisms underpinning the pathogenesis of CIPN (Balayssac et al., 2011) have been made possible by the advent of rodent models enabling new targets to be identified for use in pain therapeutics discovery programs. Such studies are discussed in the following sections of this review.

### STRUCTURAL CHANGES IN PERIPHERAL NERVES

Cancer chemotherapy agents may differentially affect specific peripheral nervous system (PNS) structures to produce neuropathy, axonopathy and/or myelinopathy that contribute to the pathogenesis of painful CIPN (Ocean and Vahdat, 2004; Balayssac et al., 2011) (**Table 1** and **Figure 1**).

Cancer chemotherapy-induced peripheral nerve injury appears to be due primarily to axonopathy (McDonald et al., 2005; Persohn et al., 2005; Gilardini et al., 2012) that is seen both in patients with CIPN (Cata et al., 2007; Burakgazi et al., 2011) and in rodent models of CIPN (Cavaletti et al., 2007; Boyette-Davis et al., 2011). Thus, peripheral nerve degeneration or small fiber neuropathy is generally accepted as underpinning the development of CIPN (Liu et al., 2010; Boyette-Davis et al., 2011; Burakgazi et al., 2011; Wang et al., 2012).

### THE LONGEST AXONS ARE THE FIRST AFFECTED

Peripheral nerves contain a variety of nerve fibers that differ in their respective morphology, degree of myelination, function and biochemical features (Gutiérrez-Gutiérrez et al., 2010). These various fiber types are differentially sensitive to the neurotoxic effects of cancer chemotherapy agents with the longest nerves having the greatest vulnerability (Wilkes, 2007; Gutiérrez-Gutiérrez et al., 2010). This may be related to their higher metabolic requirements (Chen and Chan, 2006; Mironov, 2007). Clinically, symptoms develop initially in the feet and hands, followed by proximal progression to the ankles and wrists in a “stocking and glove” distribution (Lomonaco et al., 1992; Wolf et al., 2008).

### MYELINATED FIBERS ARE DAMAGED WITH/WITHOUT ALTERED MYELIN STRUCTURE WHEREAS UNMYELINATED FIBERS ARE MOSTLY UNAFFECTED

Myelin is a lipid- and protein-rich sheath that insulates axons and facilitates faster conduction of nerve impulses compared with unmyelinated axons (Gilardini et al., 2012). Although myelinated fibers are damaged (Cata et al., 2006), perhaps even by preferential selection (Cavaletti et al., 1995; Dougherty et al., 2004), the extent to which demyelination is a key pathobiological event in CIPN is unclear. For example, using X-ray diffraction capable of detecting even subtle changes in the myelin structure, there were no structural alterations in the myelin sheath of the sciatic and optic nerves in rat models of CIPN induced using cisplatin, paclitaxel or bortezomib (Gilardini et al., 2012). These findings mirror the findings of earlier work that used fixed tissues (spinal cord and DRGs) from rodents administered the same cancer chemotherapy agents (Cavaletti et al., 1995) as well as from humans with paclitaxel-induced CIPN (Postma et al., 1995). In patients with bortezomib-induced CIPN, approximately 50% had pure small fiber neuropathy whereas the remainder had mixed small and large fiber involvement (Richardson et al., 2009).

In rat models of paclitaxel, cisplatin and bortezomib-induced CIPN, there were no clear-cut changes in the structure of internodal myelin (Gilardini et al., 2012). However, higher dosages of bortezomib were associated with an increased risk of peripheral nerve degeneration and possibly demyelination in contrast to lower dosages that nevertheless induced neuropathic pain behaviors (Zheng et al., 2012) (**Table 1**). In earlier work in patients administered paclitaxel, sural nerve biopsy revealed severe nerve fiber loss, axonal atrophy (with absence of axonal regeneration) and secondary demyelination (Sahenk et al., 1994). These peripheral nerve changes argue more for ganglionopathy than axonopathy as the most likely structural change in paclitaxel-induced neurotoxicity (Sahenk et al., 1994).

### SLOWING OF SNCV MAY NOT BE DUE TO DEMYELINATION OR DEGENERATION OF PERIPHERAL NERVE AXONS

In CIPN, reduced sensory nerve conduction velocity (SNCV) (Gilardini et al., 2012; Xiao et al., 2012), can only be attributed reliably to myelinopathy if it is associated with preserved nerve compound action potentials (Gilardini et al., 2012). Unfortunately, the technical limitations of current neurophysiological methods do not allow the relative contributions of demyelination and axonal degeneration on reduced SNCV in CIPN to be assessed (Gilardini et al., 2012). In rats with docetaxel-induced CIPN, reduced levels of myelin and mRNA encoding myelin suggest that myelin is targeted in experimental peripheral neuropathies (Roglio et al., 2009). These findings are consistent with observations of taxane-induced axonal damage and secondary demyelination (Sahenk et al., 1994; Quasthoff and Hartung, 2002; Windebank and Grisold, 2008). The extent to which individual anticancer agents or treatment combinations induce differential structural changes in peripheral nerves, is currently unclear. This is a knowledge gap that requires systematic investigation in rodent models for comparison with the changes observed in skin biopsy specimens from patients with CIPN.

### IENF LOSS WITHOUT DEGENERATION OF PERIPHERAL NERVE AXONS AND ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION

Unmyelinated fibers and terminal nerve arbors are major sites of cancer chemotherapy-induced neurotoxicity (Grisold et al., 2012) such that intraepidermal nerve fiber (IENF) loss or terminal arbor degeneration is proposed as a common lesion in various toxic neuropathies (Bennett et al., 2011; Zheng et al., 2012).

In a rodent model of paclitaxel-induced CIPN, significant IENF degeneration was not apparent by approximately 10 days after initiation of the paclitaxel treatment regimen (2 mg/kg on 4 alternate days) with peak effects observed several days later (Xiao et al., 2011). IENF degeneration and the development of pain behavior appear to be linked as both have similar delays to onset and peak effects (Xiao et al., 2011). Using electron microscopy at the time of peak pain severity, there were no signs of axonal degeneration in the saphenous nerve of these animals at a level just below the knee joint (Flatters and Bennett, 2006). Additionally, upregulation of activating transcription factor-3 (ATF-3) expression, a marker of axonal injury (Tsujino et al., 2000), was not observed in the nuclei of afferent neurons (Flatters and Bennett, 2006). Similar findings have been observed in rat

**Table 1 | Effects of clinically used cancer chemotherapy agents on peripheral nerve structure in rodent models of CIPN.**

Chemotherapy agent	Dosing regime	Rodents	PNS tissue examined	Extent of peripheral nerve damage	References
Bortezomib	ip, 0.2 mg/kg, 5 consecutive days	Male SD rats	Saphenous nerve DRGs and IENFs	IENF decrease but no degenerating axons No DRG neurons with ATF-3 positive nuclei	Zheng et al., 2012
	iv, 0.08, 0.15, 0.2, 0.3 mg/kg, 2 or 3 times a week, 4 weeks	Female Wistar rats	Sciatic nerves	Mild to moderate pathological changes involving predominantly Schwann cells and myelin; primarily characterized by myelin sheath degeneration and axonal degeneration. Unmyelinated fibers were unaffected	Cavaletti et al., 2007
	iv, 0.2 mg/kg ×3/week, 4 weeks	Female Wistar rats	Sciatic nerves Optic nerves	No pathological changes in axons and the surrounding myelin sheath Myelin degeneration in a limited number of fibers, optic nerves normal	Gilardini et al., 2012
	iv, 0.15/0.2 mg/kg × 3/week, 8 weeks	Female Wistar rats	Sciatic nerves DRGs	Nerve fiber degeneration, loss of axonal structures in the most severe cases No morphological alteration in most DRG neurons and satellite cells	Meregalli et al., 2010
	iv, 0.4/0.8 mg/kg × 2/week, 4 weeks	Female BALB/c mice	DRGs Sciatic nerves	No pathological changes in DRGs Axonal degeneration in sciatic nerves at higher dose	Carozzi et al., 2010a
	sc, 0.8, 1 mg/kg × 2/week or × 2/ week, 6 weeks	Swiss OF1 female mice	Sciatic and tibial nerves Plantar pads	Lower density of myelinated large fibers and decreased fiber diameter but no signs of degeneration	Bruna et al., 2010
Cisplatin	ip, 1 mg/kg ×3 /week, 2 mg/kg × 2/ week, 3 mg/kg ×1/week, 5 weeks	Male SD rats	Lumbar spinal cord Sciatic nerve and paw skin	Myelin sheath remains normal Unmyelinated fibers were unaffected	Authier et al., 2003a
	ip, 3 mg/kg every 3 days, 4 weeks	Male Wistar rats	Sciatic nerves	Degenerated myelinated axons with altered myelin band and altered unmyelinated axons; axonal damage without demyelination	Arrieta et al., 2011
	ip, 2/4 mg/kg × 2/week, 4 weeks	Female BALB/c mice Wistar rats	DRGs Sciatic nerves	No pathological changes in the DRGs Mild pathological changes at higher dosage regimen in sciatic nerves	Carozzi et al., 2010a; Gilardini et al., 2012
	ip, 2 mg/kg, 2/week in 4.5 weeks	Male Wistar rats	Sciatic nerves	Focal areas of demyelination and degeneration	Al Moundhri et al., 2013
Oxaliplatin	ip, 2 mg/kg, 5 consecutive days	Male SD rats	Saphenous nerves and IENFs	Oxaliplatin evoked SNCV slowing occurred in the absence of demyelination or degeneration of peripheral nerve axons	Xiao et al., 2012

*(Continued)*

Table 1 | Continued


Chemotherapy agent	Dosing regime	Rodents	PNS tissue examined	Extent of peripheral nerve damage	References
	ip, 2 mg/kg, 4 alternate days	Male SD rats	Nerve fibers	Significantly fewer IENFs	Boyette-Davis and Dougherty, 2011
	ip, 4 mg/kg, 2/week in 4.5 weeks	Male Wistar rats	Sciatic nerves	Focal areas of demyelination and degeneration	Al Moundhri et al., 2013
	ip, 3, 6 or 12 mg/kg, single	Male SD rats	Lumbar spinal cord	No difference in immunoreactivity for CGRP but substance P was significant higher than for vehicle control group (12 vs. 5%)	Ling et al., 2007
Vincristine	iv, 50, 100 and 150 $\mu$ g/kg, every second day, up to five injections	Male SD rats	Paw skin	Myelin sheaths remained unaffected	Authier et al., 2003b
	ip, 0.2 mg/kg $\times$ 1/week, 5 weeks, 0.1 mg/kg and increase by 0.05 mg/kg each week, 5 weeks	Male rats	Sciatic nerve	Reduction in action potential amplitude associated with axonal degeneration with or without minor changes of segmental demyelination	Ja'afar et al., 2006
Paclitaxel	ip, single 32 mg/kg	Male SD rats	Lumbar spinal cord, Sciatic nerve and paw skin	Axonal degenerative changes while Schwann cells and myelin sheaths remained normal	Authier et al., 2000b
	ip, 0.5, 1, 2, 6 or 8 mg/kg, 4 alternate days	Male SD rats	DRGs Sciatic nerves	No degeneration, no DRG neurons with ATF-3 positive nuclei No degeneration of myelinated or unmyelinated axons	Polomano et al., 2001; Flatters and Bennett, 2006; Bennett et al., 2011
	iv, 18 mg/kg, D0 and D3	Male SD rats	DRGs Sciatic nerve	ATF-3 upregulation	Peters et al., 2007
	ip, 8 mg/kg $\times$ 2/week, 4 weeks	Male Wistar rats	Sciatic nerves	Axonal damage without demyelination	Arrieta et al., 2011
	ip, 16mg/kg $\times$ 1/week, 4 weeks iv, 5, 10, 12.5 mg/kg $\times$ 1/week, 4 weeks	Female Wistar rats	Axons (sciatic nerve)	Most myelinated fibers have normal histology, some fibers show axonal degeneration	Persohn et al., 2005
	ip, 12.5 mg/kg $\times$ 1/week, 9 weeks	Female Wistar rats	DRGs	Increased immunohistochemical staining for ATF-3	Jamieson et al., 2007
	iv, 10 mg/kg $\times$ 1/week, 4 weeks	Female Wistar rats	Sciatic nerves Optic nerves	No pathological changes in axons and surrounding myelin sheath	Gilardini et al., 2012
	iv, 18 mg/kg, twice, every 3 days	Male SD rats	Trigeminal ganglia DRGs	Increased immunohistochemical staining for ATF-3	Jimenez-Andrade et al., 2006
	ip, 4.5 mg/kg, 25 mg/kg, or 60 mg/kg	Female C57BL/6 mice	Sciatic nerves	Macrophage-mediated demyelination, axons completely stripped of their myelin sheaths and surrounded by the cytoplasm of debris-filled phagocytes in some cases	Mo et al., 2012

(Continued)

Table 1 | Continued

Chemotherapy agent	Dosing regime	Rodents	PNS tissue examined	Extent of peripheral nerve damage	References
	ip, 8 or 16 mg/kg × 1/week, 5 weeks	Female Wistar rats	Sciatic/peroneal nerves and DRGs	Decrease in number of large myelinated fibers, but not due to a reduction in myelin thickness, mild axonal loss with minimal demyelination	Cavaletti et al., 1995
	iv, 50.70 mg/kg, × 1/week, 4 weeks	Female BALB/c mice	DRGs Sciatic nerves	No pathological changes	Carozzi et al., 2010a
	ip, 30 mg/kg once or several times at different intervals	BDF1 mice	Dorsal funiculus Dorsal spinal roots Peripheral nerves	Nerve fiber degeneration characterized by axonal and myelin fragmentations and phagocytosis	Mimura et al., 2000

ATF, activating transcription factor; CGRP, calcitonin gene-related peptide; DRG, dorsal root ganglia; IENFs, intraepidermal nerve fibers; iv, intravenous injection; ip, intraperitoneal injection; sc, subcutaneous; SD, Sprague-Dawley; SNCV, sensory nerve conduction velocity.



models of vincristine, oxaliplatin and bortezomib-induced CIPN such that neuropathic pain behaviors were associated with IENF degeneration in the absence of peripheral nerve axonal degeneration (Aley et al., 1996; Tanner et al., 1998; Topp et al., 2000; Siau and Bennett, 2006; Bennett et al., 2011).

Clinically, there is IENF loss in patients with CIPN (Boyette-Davis et al., 2011; Giannoccaro et al., 2011) despite these individuals having normal peripheral nerve axon counts (Holland et al., 1998; Herrmann et al., 1999) and normal nerve conduction results (Periquet et al., 1999; Devigili et al., 2008; Løseth et al.,

2008). This led Holland et al. (1998) to coin the term “terminal axonopathy” that is akin to the more recently promulgated “terminal arbor degeneration” concept (Bennett et al., 2011). In patients, an increase in the swelling ratio of IENFs appeared to be predictive of a decrease in IENF density and this was correlated with the severity of painful neuropathy induced in the feet by paclitaxel (CIPN), diabetes, AIDS, and idiopathic neuropathy (Schmidt et al., 1997; Lauria et al., 2003). However, administration of much larger doses of cancer chemotherapy agents in rats, such as paclitaxel either as a single bolus (12.5–32 mg/kg) (Authier et al., 2000b; Jamieson et al., 2007) or as cumulative doses (8 and 16 mg/kg once-weekly for 5 weeks) (Cavaletti et al., 1995) or bortezomib at 2.4–4.8 mg/kg (Cavaletti et al., 2007; Meregalli et al., 2010; Gilardini et al., 2012), resulted in degeneration of peripheral nerve axons and DRG neurons, together with ATF-3 up-regulation in DRG neurons (Jamieson et al., 2007; Peters et al., 2007). Thus, the extent to which peripheral nerve axons are damaged by chemotherapy agents appear to be directly related to the dosing regimen (Table 1).

Comparatively high concentrations of paclitaxel are found in the DRGs relative to peripheral nerve and spinal cord (Herrmann et al., 1999), that may be underpinned by the fact that the subepidermal axon bundles in peripheral nerves lack a perineurium (a component of the blood-nerve barrier). Additionally, anterograde transport of paclitaxel from sensory neuron cell bodies to the IENFs would take time for toxic levels to be reached in the terminal arbors (Bennett et al., 2011). Such a lag period may potentially explain the coasting effect, i.e., the delay between treatment cessation relative to the loss of IENFs and the appearance of pain hypersensitivity (Bennett et al., 2011).

IENF degeneration and abnormal spontaneous discharge of primary afferent nerve fibers in rat models of CIPN may be underpinned by mitochondrial dysfunction and consequent energy deficiency (Boyette-Davis and Dougherty, 2011; Xiao et al., 2012; Zheng et al., 2012). Mitochondria are concentrated in regions of high metabolic demand (Chen and Chan, 2006; Mironov, 2007) such as sensory terminal boutons that are packed with mitochondria (Breathnach, 1977; Ribeiro-Da-Silva et al., 1991; Bennett et al., 2011). The high energy requirement of the intraepidermal terminal arbor is thought to be due, at least in part, to the constant degeneration and regeneration (remodeling) of the arbor in its ever changing microenvironment (Bennett et al., 2011). This is because the epidermis is in a continuous state of renewal with a total epidermal turnover time of approximately 45 days in humans (Bergstresser and Taylor, 1977).

### MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS

Mitochondria are the energy-generating structures in cells with their dysfunction implicated in the pathogenesis of cancer and a range of neurodegenerative diseases (Florea and Büsselberg, 2011). Abnormalities in mitochondrial structure and function in peripheral sensory nerve fibers are postulated as key CIPN mechanisms and appear to be correlated directly with pain behavior (Flatters and Bennett, 2006; Zheng et al., 2012). In multiple myeloma patients administered cycles of bortezomib in combination with dexamethasone, bortezomib toxicity on mitochondria resulted in impairment of the electrogenic

$\text{Na}^+ - \text{K}^+$ -ATPase-dependent pump resulting in axonal membrane depolarization that preceded axonal degeneration (Nasu et al., 2013). In patients with vincristine and bortezomib-induced CIPN, there were significant changes in the expression of genes involved in the control of mitochondrial function in myeloma plasma cells and peripheral blood (Broyl et al., 2010). Interestingly, exposure of cultured DRG neurons to cisplatin and paclitaxel *in vitro* induced mitochondrial damage that was reversed by pretreatment with the antioxidant,  $\alpha$ -lipoic acid (Melli et al., 2008). Additionally, the development of CIPN in rodent models (Table 2) and patients (Table 3) can be prevented by treatment with drugs that enhance mitochondrial function. Conversely, as mitochondrial poisons exacerbate neuropathic pain behaviors in rodent models of CIPN (Xiao and Bennett, 2012), CIPN appears to be linked to mitotoxicity (Figure 1).

### MITOTOXICITY

#### *Direct mitochondrial DNA (mtDNA) damage*

Cisplatin forms adducts with mitochondrial DNA resulting in direct mitochondrial DNA (mtDNA) damage that is a novel mechanism for cisplatin-induced CIPN and is distinct from the established nuclear DNA (nDNA) damage pathway (Podratz et al., 2011). DRG neurons accumulate high levels of cisplatin-DNA adducts both *in vitro* and *in vivo* (McDonald et al., 2005; Ta et al., 2006) such that the cisplatin concentration in the PNS is comparable with that in tumor tissue (Gregg et al., 1992; Screnci and McKeage, 1999; Melli et al., 2008).

Cisplatin-DNA adducts can be removed and DNA repaired by the nucleotide excision repair (NER) system that is present in nDNA (McDonald et al., 2005; Podratz et al., 2011), in contrast to mtDNA where the NER system is absent (Croteau et al., 1999). Hence, cisplatin-mtDNA adducts inhibit mtDNA replication and mtRNA transcription to cause mitochondrial degradation (Podratz et al., 2011) in DRG neurons.

#### *Increased mitochondrial swelling and vacuolation in peripheral nerve axons*

In rat models of paclitaxel, oxaliplatin and bortezomib-induced CIPN, the number of swollen and vacuolated mitochondria in the axons of A- and C-primary afferent sensory nerve fibers was significantly higher (37.3 and 152%, respectively) than for vehicle-treated control rats (Xiao et al., 2011, 2012; Zheng et al., 2012). These changes resulted in mitochondrial dysfunction characterized by significant deficits in mitochondrial respiration and ATP production that were rescued by prophylactic treatment with acetyl-L-carnitine. The latter is an acetylated derivative of the natural amino acid, L-carnitine, that has an essential role in the transport of long-chain free fatty acids into mitochondria (Zheng et al., 2011, 2012). Interestingly, there was a relative sparing of mitochondria in the corresponding peripheral nerve Schwann cells (Flatters and Bennett, 2006; Zheng et al., 2011, 2012; Xiao and Bennett, 2012; Xiao et al., 2012).

In DRG satellite cells, bortezomib induced intracytoplasmic vacuolation characterized by damage to mitochondria and the endoplasmic reticulum (Cavaletti et al., 2007). These changes

**Table 2 | Summary of pharmacological agents that enhance mitochondrial function as well as prevent and/or alleviate CIPN in rodent models.**

Pharmacological agent	Rodent model	Efficacy outcome	Dose and route	References
Acetyl-L-carnitine (antioxidant)	Paclitaxel	+ (intervention)	100 mg/kg, p.o. Daily ×10	Flatters et al., 2006
	Paclitaxel	+(prophylactic)	50 and 100 mg/kg, p.o. Daily ×21	Flatters et al., 2006
	Paclitaxel	+ (prophylactic and intervention)	100 mg/kg, s.c. Daily	Ghirardi et al., 2005
	Vincristine	+ (prophylactic and intervention)	100 mg/kg, s.c. Daily	Ghirardi et al., 2005
	Cisplatin	+ (prophylactic and intervention)	100 mg/kg, s.c. Daily	Ghirardi et al., 2005
	Oxaliplatin	+ (prophylactic and intervention)	100 mg/kg, s.c. Daily	Orlando et al., 2005
	Oxaliplatin	+ (prophylactic)	100 mg/ml/kg, p.o. Daily	Xiao et al., 2012
Olesoxime	Paclitaxel	+ (prophylactic)	3 or 30 mg/kg, p.o. Daily	Xiao et al., 2009
	Oxaliplatin	+ (prophylactic)	30 mg/ml/kg, p.o. Daily	Xiao et al., 2012
Silibinin(antioxidant)	Oxaliplatin	+ (prophylactic)	100 mg/kg, p.o. Daily	Di Cesare Mannelli et al., 2012
Allopregnanolone	Oxaliplatin	+ (prophylactic and intervention)	2 or 4 mg/kg, Every 2 or 4 days	Meyer et al., 2011

*p.o., per os; s.c., subcutaneous.*

**Table 3 | Clinical trial evidence for the role antioxidants in the relief of CIPN.**

Medications	Patients involved	Chemotherapy agent	Trial	Efficacy	Weather interfere with anticancer efficacy	References
$\alpha$ -Lipoic acid (Treatment)	14	Docetaxel and isplatin	Randomised	Yes	–	Gedlicka et al., 2003
	15	Oxaliplatin	–	Yes	–	Gedlicka et al., 2002
Acetyl-L-carnitine (Treatment)	25	Cisplatin and/or Paclitaxel	–	Yes	–	Bianchi et al., 2005
	27	Cisplatin and/or Paclitaxel	–	Yes	–	Maestri et al., 2005
	409	Taxane-based	RCT	No; pain worsened	–	Hershman et al., 2013
Glutathione (Prevention)	31	Cisplatin	Randomized	Yes	No	Colombo et al., 1995
	151	Cisplatin	–	Yes	–	Smyth et al., 1997
	27	Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX)	Randomized	Yes	No	Milla et al., 2009
	52	Oxaliplatin-based	RCT	Yes	–	Cascinu et al., 2002
Amifostine (Prevention)	92	Oxaliplatin (FOLFOX4)	Randomized	Yes	No	Lu et al., 2008
	187	Paclitaxel and Carboplatin	Randomized	yes	–	Lorusso et al., 2003
	27	Cisplatin and Paclitaxel	–	Not really	–	Moore et al., 2003
	38	Paclitaxel and Carboplatin	Randomized	Yes	–	Kanat et al., 2003
	72	Paclitaxel and Carboplatin-based	RCT	Yes	±	Hilpert et al., 2005
Org 2766 (Prevention)	196	Cisplatin and cyclophosphamide	–	No	–	Roberts et al., 1997
	55	Cisplatin and cyclophosphamide	RCT	Yes	No	van et al., 1990
N-acetylcysteine (Prevention)	14	Cisplatin-based	Randomized placebo controlled	Yes	–	Lin et al., 2006

*RCT, Randomized, Double-Blind, Placebo-Controlled Trial.*

appear to be underpinned by activation of the mitochondrial-based apoptotic pathway including caspase activation (Broyl et al., 2010; Lee et al., 2012) as well as dysregulation of calcium homeostasis (Landowski et al., 2005). Paclitaxel-induced mitochondrial damage was confined to the axons of primary afferent sensory with sparing of motor neurons (Xiao et al., 2011). The high and persistent exposure of primary sensory neuron cell bodies in the DRGs to paclitaxel may contribute to this selective effect (Xiao et al., 2011).

### **Opening of the mPTP and dysregulation of calcium homeostasis**

Paclitaxel opens the mitochondrial permeability transition pore (mPTP), a multi-molecular complex containing a voltage-dependent anion channel that induces mitochondrial calcium release (Kidd et al., 2002; Flatters and Bennett, 2006). Acetyl-L-carnitine can prevent mPTP opening (Pastorino et al., 1993) and is associated with a reduction in paclitaxel, oxaliplatin and bortezomib-induced CIPN when administered prophylactically in rodents (Jin et al., 2008; Bujalska and Makulska-Nowak, 2009; Carozzi et al., 2010b; Xiao et al., 2012; Zheng et al., 2012).

Mitochondria have a large calcium buffering capacity and so impaired calcium uptake or increased calcium leakage from mitochondrial stores may have a pathological role in CIPN (Jaggi and Singh, 2012). This notion is supported by the fact that vincristine-induced neurotoxicity in rats was reversed by drugs that reduce elevated intra-neuronal calcium concentrations (Muthuraman et al., 2008; Kaur et al., 2010). In other work, increased expression levels of the  $\alpha_2\delta$  subunit of voltage-gated  $\text{Ca}^{2+}$  channels in the DRGs were correlated with the development of mechanical allodynia (Luo et al., 2001). Conversely, drugs that bind to the  $\alpha_2\delta$  subunit such as gabapentin (Flatters and Bennett, 2004; Xiao et al., 2007) and pregabalin (Saif et al., 2010; Nakashima et al., 2012; Peng et al., 2012), as well as the L-type calcium channel blocker, lercanidipine (Saha et al., 2012), showed efficacy for prevention of CIPN in rodent models and patients (Nguyen and Lawrence, 2004; Saif et al., 2010; Nakashima et al., 2012).

A retrospective review of 69 patients administered oxaliplatin concluded that calcium channel blockers reduce CIPN (Tatsushima et al., 2013). Although intravenous  $\text{Ca}^{2+}/\text{Mg}^{2+}$  infusions reportedly attenuate the development of oxaliplatin-induced CIPN without compromising cancer treatment efficacy (Wolf et al., 2008; Kurniali et al., 2010; Wen et al., 2013), there are lingering concerns regarding a negative effect on cancer chemotherapy treatment efficacy. Hence, this needs to be evaluated for each class of cancer chemotherapy agent (Kurniali et al., 2010).

### **OXIDATIVE STRESS**

In a rat model of oxaliplatin-induced neuropathy, markers of oxidative stress including lipid peroxidation, carbonylated proteins, and DNA oxidation increased in the systemic circulation, the sciatic nerve and the lumbar spinal cord (Di Cesare Mannelli et al., 2012), with these changes prevented by antioxidant treatment (Di Cesare Mannelli et al., 2012; Nasu et al., 2013). Similarly, production of reactive oxygen species (ROS) was increased by cisplatin (Florea and Büsselberg, 2011), and bortezomib (Wang et al., 2011). In patients receiving docetaxel for the treatment of

cancer, the occurrence of grade  $\geq 2$  CIPN was more frequent in individuals homozygous for *GSTP1* <sup>105</sup>Ile allele, that encodes glutathione S-transferase pi 1 (GSTP1), an enzyme involved in the regulation of oxidative stress (Mir et al., 2009).

A role for oxidative stress in the pathobiology of CIPN is supported by multiple *in vitro* and *in vivo* studies showing that antioxidants have neuroprotective effects in CIPN (Table 2). In particular, the non-specific ROS scavenger, phenyl N-tert-butyl nitron (PBN), administered according to an intervention protocol in rats administered paclitaxel, attenuated development of mechanical (Kim et al., 2010) and cold hypersensitivity in the hindpaws (Fidanboyly et al., 2011). Conversely, for rats administered auranofin, a compound that increased oxidative stress, oxaliplatin and paclitaxel-induced neuropathic pain behaviors were exacerbated (Xiao and Bennett, 2012). Furthermore, as the superoxide-specific scavenger, TEMPOL (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) neither alleviated established paclitaxel-induced CIPN nor prevented its development in rodents, ROS but not superoxide radicals alone, are implicated in CIPN pathogenesis (Fidanboyly et al., 2011).

Although a benefit of antioxidants for the treatment and/or prevention of CIPN has been shown in multiple clinical studies (Table 3), most did not report on their impact on anticancer efficacy, and so this is a knowledge gap.

Increased spinal dorsal horn levels of peroxynitrite in rats with paclitaxel-induced CIPN (Doyle et al., 2012) implicate a role for reactive nitrogen species (RNS) in CIPN pathogenesis (Kamei et al., 2005; Mihara et al., 2011). Augmented peroxynitrite production may occur via two mechanisms with the first involving activation of nitric oxide synthase and NADPH oxidase to induce formation of the peroxynitrite precursors, NO and SO (Doyle et al., 2012). The second involves inactivation of the enzyme (manganese superoxide dismutase) that catalyzes peroxynitrite degradation (Doyle et al., 2012). This latter mechanism is supported by observations that peroxynitrite decomposition catalysts ( $\text{FeTMPyP}^{5+}$  and  $\text{MnTE-2-PyP}^{5+}$ ) prevented development of neuropathic pain behaviors in rat models of paclitaxel, oxaliplatin and bortezomib-induced CIPN (Doyle et al., 2012; Janes et al., 2013).

CIPN-induced nitro-oxidative stress results in increased production of proinflammatory cytokines (TNF- $\alpha$  and IL-1 $\beta$ ), reduced production of anti-inflammatory cytokines (IL-10 and IL-4), as well as post-translational nitration of glutamate transporters and glutamine synthetase in astrocytes, the net result of which is enhanced pro-nociceptive glutamatergic signaling (Doyle et al., 2012). Treatment strategies that shift the balance in favor of anti-inflammatory cytokines have potential for slowing the development and progression of peripheral neuropathy in patients receiving cancer chemotherapy drugs (Wang et al., 2012).

### **LOSS OF HEAT SENSITIVITY IN CIPN**

#### **DIVERSE RESULTS OF HEAT SENSITIVITY IN CIPN**

Primary afferent nerve fibers affected by cancer chemotherapy drug treatment regimens often exhibit both positive and negative sensory phenomena resulting in altered nociceptive thresholds (Nahman-Averbuch et al., 2011). Increased nociceptive thresholds may develop due to nerve fiber loss whereas reduced



nociceptive thresholds may develop as a result of peripheral and central sensitization (Nahman-Averbuch et al., 2011).

In general, there is heat hypoalgesia or a loss of heat sensitivity in patients with CIPN (Dougherty et al., 2004; Cata et al., 2006; Attal et al., 2009; Nahman-Averbuch et al., 2011) as well as in most rodent models of this condition (Authier et al., 2000a, 2003a; Fischer et al., 2001; Cata et al., 2006, 2008; Garcia et al., 2008; Hori et al., 2010; Xiao et al., 2012; Zheng et al., 2012). Additionally, cold allodynia is a characteristic symptom of painful CIPN in patients (Cata et al., 2006) as well as in rodent models (Authier et al., 2003a,b; Cata et al., 2006; Xiao et al., 2012).

#### **LOSS OF HEAT SENSITIVITY MAY RESULT FROM SENSITIZATION/DESENSITIZATION OF TRPV1**

Loss of heat sensibility may be due to myelinated A-fiber damage and loss of transient receptor potential vanilloid 1 (TRPV1)-expression (Woodbury et al., 2004) C-fibers (Dougherty et al., 2004).

A small increase in ROS production activates transcriptional machinery to enhance TRPV1 expression levels in C-fibers (Suzukawa et al., 2000; Kishi et al., 2002; Schmeichel et al., 2003). Additionally, nerve growth factor (NGF) facilitates increased TRPV1 expression by nociceptive C-fibers and directly increases the number of neurons that respond to noxious heat (Stucky and Lewin, 1999; Amaya et al., 2004). Enhanced thermal sensitivity results from sensitization (phosphorylation) of TRPV1, transduced by protein kinase C (PKC) (Kamei et al., 2001; Di Marzo et al., 2002; Hong and Wiley, 2005) and/or mitogen-activated protein kinases (MAPK) (Ji et al., 2002; Clapham, 2003). In the DRGs and hindpaw skin of hyperalgesic and hypoalgesic mice, TRPV1 expression levels are increased and decreased, respectively (Pabbidi et al., 2008). Thermal hypoalgesia may be underpinned by reduced TRPV1 expression and function, that in turn may lead to more serious complications (Pabbidi et al., 2008).

Other TRP channels implicated in the pathogenesis of CIPN include TRPA1 that is expressed by nociceptors and is activated by oxidative stress. The transient benefit of the TRPA1 antagonist HC-030031 in mice with bortezomib or oxaliplatin-induced CIPN, suggests a role for early activation/sensitization of TRPA1 by oxidative stress by-products in establishment of CIPN (Trevisan et al., 2013). Additionally, TRPV4 may contribute to paclitaxel-induced mechanical hypersensitivity in CIPN (Alessandri-Haber et al., 2004), whereas TRPA1 and TRPM8 over-expression were induced in the DRGs by oxaliplatin (Anand et al., 2010; Descoeur et al., 2011). Cisplatin and oxaliplatin-induced neurotoxicity of DRG neurons in rats results in p38 MAPK and ERK1/2 activation as well as a reduction in JNK/SapK phosphorylation (Scuteri et al., 2009, 2010). Apart from the foregoing, a broad array of other molecular mechanisms have been implicated in the pathobiology of CIPN and these have been reviewed elsewhere (Jaggi and Singh, 2012; Wang et al., 2012) and are summarized in **Table 4**.

#### **BETWEEN CANCER CHEMOTHERAPY AGENT DIFFERENCES IN THE PATHOBIOLOGY OF CIPN**

CIPN affects sensory nerves predominantly; while motor, autonomic or CNS (Schlegel, 2011) involvement is rare (Grisold

et al., 2012). Sensory nerves allow the perception of touch, pain, temperature (small fiber); position, and vibration (large fiber) (Wilkes, 2007). The persistent cumulative injury caused by cancer chemotherapy agents most often affects sensory nerve cell bodies in the DRGs (e.g., cisplatin) and/or the afferent and efferent axons lying outside the spinal cord (e.g., paclitaxel, oxaliplatin) (Quasthoff and Hartung, 2002).

It is generally assumed that platinum compounds irreversibly bind to DNA thereby inducing apoptosis of primary sensory neurons (Velasco and Bruna, 2010). Antitubulins (paclitaxel, docetaxel and vincristine) bind to microtubules, interrupt axonal transport, target the soma of sensory neurons as well as nerve axons, to induce neuronal death (Bennett, 2010; Cavaletti and Marmiroli, 2010; Velasco and Bruna, 2010). In cultured rat DRG neurons, paclitaxel increased the release of the pro-nociceptive neuropeptide, substance P, whereas oxaliplatin did not; the extent to which this difference contributes to differences in paclitaxel and oxaliplatin-induced peripheral nerve neurotoxicity, remains to be determined (Tatsushima et al., 2011). In patients with CIPN, sensory testing shows that peripheral nerve abnormalities appear to have distinct features depending upon the cancer chemotherapeutic agent involved (Cata et al., 2006), but the mechanistic basis remains unclear (Gilchrist, 2012).

Conversely, it is also likely that one or more pathobiologic mechanisms are shared among anticancer agents (Dougherty et al., 2004; Grisold et al., 2012; Zheng et al., 2012). For example, nerve biopsies from rodents and patients administered cisplatin (Dougherty et al., 2004), paclitaxel, oxaliplatin, vincristine, and bortezomib show similar morphological changes (loss of IENFs) even though these compounds have different neurotoxic targets (Flatters and Bennett, 2006; Bennett et al., 2011; Boyette-Davis et al., 2011; Burakgazi et al., 2011; Pachman et al., 2011; Xiao et al., 2012; Zheng et al., 2012). Additionally, mitotoxicity appears to be a factor in common in the pathobiology of CIPN induced by the taxane, paclitaxel, the platinum-complex agent, oxaliplatin, and the proteasome-inhibitor, bortezomib, in rodent models (Zheng et al., 2011, 2012; Xiao et al., 2012).

Although CIPN may share mediators in common with other types of neuropathic pain, the disparity in efficacy of anti-neuropathic agents suggests underlying mechanistic differences (Farquhar-Smith, 2011). For example, NGF deficiency in peripheral nerves is a phenomenon in common between cisplatin-induced CIPN (Cavaletti et al., 2002) and early diabetic neuropathy (Anand, 2004). Hypersensitivity to heat is common in the CCI-rat model of neuropathic pain, but it is very minor or absent in rat models of CIPN (Bennett, 2010) and in patients with either CIPN (Dougherty et al., 2004; Hershman et al., 2011) or diabetic neuropathy (Sorensen et al., 2006; Nahman-Averbuch et al., 2011). Such dissociations indicate that the pathophysiological mechanisms responsible for peripheral nerve injury and neuropathic pain are at least in part dependent upon the cause of the nerve injury (Bennett, 2010).

#### **CONCLUSION**

CIPN is characterized by multiple sensory changes including the development of (i) mechanical allodynia, whereby light pressure or touch that would normally be perceived as innocuous,

**Table 4 | Molecular mechanisms implicated in the pathogenesis of CIPN.**

Chemotherapy agents	Rodent CIPN models and human studies	Mechanism	References
Cisplatin Oxaliplatin	Male C57BL6 mice Female Wistar rats-cultured DRGs	Up-regulation of TRPV1, TRPA1 and TRPM8 TRPM8 and/or TRPA1 over-expression; respond to cold allodynia	Anand et al., 2010; Ta et al., 2010; Descoeur et al., 2011; Goswami, 2012
Cisplatin Oxaliplatin	Male SD rats	Activation of p38 MAPK and ERK1/2, along with downregulation of SAPK/JNK in cultured DRGs	Scuteri et al., 2010
Vincristine Paclitaxel	Male SD rats	Calcium increase either by influx of extracellular Ca <sup>2+</sup> or release from mitochondrial intracellular stores, binding to $\alpha_2\delta$ subunit of Ca <sup>2+</sup> channel; decreased calcium flux	Xiao et al., 2007; Kaur et al., 2010
Paclitaxel	Human neuroblastoma cell line, SHSY-5Y	Activation of calpain, degradation of neuronal calcium sensor (NCS-1), and loss of intracellular calcium signaling	Benbow et al., 2012
Paclitaxel Vincristine Cisplatin Oxaliplatin Bortezomib	Female/male Wistar rats Male SD rats	NMDA receptor antagonists antagonize CIPN in prevention but not intervention protocol or only at high doses	Pascual et al., 2010; Mihara et al., 2011
Oxaliplatin Cisplatin Vincristine	Male mice- C57BL6J Male SD rats	DNA damage	Brederson et al., 2012; Ta et al., 2013
Oxaliplatin	Male SD rats	Increase in PKC activity in supra-spinal regions	Norcini et al., 2009
Paclitaxel but Not Oxaliplatin	Male SD rats- cultured DRG	Increased release of substance P and altered CGRP and somatostatin release	Tatsushima et al., 2011
Cisplatin Paclitaxel	Female patients Female Wistar rats	Decrease in NGF levels by Total Neuropathy Score (TNS) in patient and in rat plasma samples	Cavaletti et al., 2002, 2004
Oxaliplatin	Patients Rats	Dysfunction of axonal Na <sup>+</sup> channels Dysfunction of axonal K <sup>+</sup> channels	Park et al., 2011; Kagiava et al., 2013
Vincristine	Female Inbred C57BL mice	Increase in 5-HT <sub>2A</sub> receptors in dorsal horn and DRGs	Hansen et al., 2011
Paclitaxel	Male C57BL/6 mice	Antagonists of Kinin B1 and B2 receptors attenuate CIPN	Costa et al., 2011
Cisplatin Paclitaxel	Male SD rats	Activation of cannabinoid CB2 receptors	Deng et al., 2012
Paclitaxel	Female WT and $\sigma_1$ -KO CD-1mice	Antagonists of the sigma-1 receptor attenuate CIPN	Nieto et al., 2012

*(Continued)*

Table 4 | Continued

Chemotherapy agents	Rodent CIPN models and human studies	Mechanism	References
Oxaliplatin	Patients	Integrin beta-3 L33P is related to CIPN severity but not the development of CIPN	Antonacopoulou et al., 2010
Paclitaxel Cisplatin	Male SD rats	Inflammation	Alaedini et al., 2008; Wang et al., 2012
Taxol Oxaliplatin	Balb/c mice	Increased glial fibrillary acidic protein expression in satellite glial cells, and gap junction-mediated coupling between satellite glial cells	Warwick and Hanani, 2013
Oxaliplatin	Male SD rats	Activation of spinal astrocytes accompanied by increased expression of astrocyte-astrocyte gap junction connections via Cx43	Yoon et al., 2013
		Activation of drug transporters (nervous system transporters including glutamate, copper transporters, etc.)	Ceresa and Cavaletti, 2011
		Patient's genetic background	Windebank and Grisold, 2008; Broyl et al., 2010; Grisold et al., 2012

*CGRP*, Calcitonin gene related peptide; *IENFs*, intraepidermal nerve fibers; *MAPK*, mitogen activated protein kinase; *NMDA* (*N*-methyl-*D*-aspartate) receptors; *TRPV*, transient receptor potential vanilloid.

evokes pain, (ii) cold allodynia whereby cold temperature evokes a painful sensation, (iii) slowing of SNCV, and (iv) loss of heat sensitivity.

Although the precise pathobiology of CIPN remains to be fully elucidated, recent research implicates “terminal arbor degeneration” (Bennett et al., 2011) and the associated mitochondrial dysfunction and mitotoxicity (Podratz et al., 2011; Zheng et al., 2012) as well as oxidative stress (Nasu et al., 2013). Additional investigation is required to better define subtle between-chemotherapy agent differences in the pathogenesis of CIPN as a means for enhancing rational discovery of novel treatments with potential to prevent and/or attenuate the development of CIPN.

## REFERENCES

- Alaedini, A., Xiang, Z., Kim, H., Sung, Y. J., and Latov, N. (2008). Up-regulation of apoptosis and regeneration genes in the dorsal root ganglia during cisplatin treatment. *Exp. Neurol.* 210, 368–374. doi: 10.1016/j.expneurol.2007.11.018
- Alessandri-Haber, N., Dina, O. A., Yeh, J. J., Parada, C. A., Reichling, D. B., and Levine, J. D. (2004). Transient receptor potential vanilloid 4 is essential in chemotherapy-induced neuropathic pain in the rat. *J. Neurosci.* 24, 4444–4452. doi: 10.1523/JNEUROSCI.0242-04.2004
- Aley, K. O., Reichling, D. B., and Levine, J. D. (1996). Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. *Neuroscience* 73, 259–265. doi: 10.1016/0306-4522(96)00020-6
- Al Moundhri, M. S., Al-Salam, S., Al Mahrouqee, A., Beegam, S., and Ali, B. H. (2013). The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical, and histopathological studies. *J. Med. Toxicol.* 9, 25–33. doi: 10.1007/s13181-012-0239-x
- Amaya, F., Shimamoto, G., Nagano, M., Ueda, M., Hashimoto, S., Tanaka, Y., et al. (2004). NGF and GDNF differentially regulate TRPV1 expression that contributes to development of inflammatory thermal hyperalgesia. *Eur. J. Neurosci.* 20, 2303–2310. doi: 10.1111/j.1460-9568.2004.03701.x
- Anand, P. (2004). “Neurotrophic factors and their receptors in human sensory neuropathies,” in *Ngf and Related Molecules in Health and Disease*, ed L. C. L. Aloe (Italy: Elsevier), 477–492.
- Anand, U., Otto, W. R., and Anand, P. (2010). Sensitization of capsaicin and icilin responses in oxaliplatin treated adult rat DRG neurons. *Mol. Pain* 6. doi: 10.1186/1744-8069-1186-1182
- Antonacopoulou, A. G., Argyriou, A. A., Scopa, C. D., Kottorou, A., Kominea, A., Peroukides, S., et al. (2010). Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? *Eur. J. Neurol.* 17, 963–968. doi: 10.1111/j.1468-1331.2010.02966.x
- Argyriou, A. A., Cavaletti, G., Briani, C., Velasco, R., Bruna, J., Campagnolo, M., et al. (2013). Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. *Cancer* 119, 438–444. doi: 10.1002/cncr.27732
- Arrieta, O., Hernandez-Pedro, N., Fernandez-Gonzalez-Aragon, M. C., Saavedra-Perez, D., Campos-Parra, A. D., Rios-Trejo, M. A., et al. (2011). Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer. *Neurology* 77, 987–995. doi: 10.1212/WNL.0b013e31822e045c
- Attal, N., Bouhassira, D., Gautron, M., Vaillant, J. N., Mitry, E., Lepere, C., et al. (2009). Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. *Pain* 144, 245–252. doi: 10.1016/j.pain.2009.03.024

- Authier, N., Fialip, J., Eschalier, A., and Coudore, F. (2000a). Assessment of allodynia and hyperalgesia after cisplatin administration to rats. *Neurosci. Lett.* 291, 73–76. doi: 10.1016/S0304-3940(00)01373-2
- Authier, N., Gillet, J.-P., Fialip, J., Eschalier, A., and Coudore, F. (2000b). Description of a short-term Taxol  $\delta$ -induced nociceptive neuropathy in rats. *Brain Res.* 887, 239–249. doi: 10.1016/S0006-8993(00)02910-3
- Authier, N., Gillet, J.P., Fialip, J., Eschalier, A., and Coudore, F. (2003a). An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. *Exp. Neurol.* 182, 12–20. doi: 10.1016/S0014-4886(03)00003-7
- Authier, N., Gillet, J. P., Fialip, J., Eschalier, A., and Coudore, F. (2003b). A new animal model of vincristine-induced nociceptive peripheral neuropathy. *Neurotoxicology* 24, 797–805. doi: 10.1016/S0161-813X(03)00043-3
- Balayssac, D., Cayre, A., Authier, N., Bourdu, S., Penault-Llorca, F., Gillet, J. P., et al. (2005). Patterns of P-glycoprotein activity in the nervous system during vincristine-induced neuropathy in rats. *J. Peripher. Nerv. Syst.* 10, 301–310. doi: 10.1111/j.1085-9489.2005.10308.x
- Balayssac, D., Ferrier, J., Descoeur, J., Ling, B., Pezet, D., Eschalier, A., et al. (2011). Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. *Expert Opin. Drug Saf.* 10, 407–417. doi: 10.1517/14740338.2011.543417
- Benbow, J. H., Mann, T., Keeler, C., Fan, C. P., Hodsdon, M. E., Lolis, E., et al. (2012). Inhibition of paclitaxel-induced decreases in calcium signaling. *J. Biol. Chem.* 287, 37907–37916. doi: 10.1074/jbc.M112.385070
- Bennett, G. J. (2010). Pathophysiology and animal models of cancer-related painful peripheral neuropathy. *Oncologist* 15, 9–12. doi: 10.1634/theoncologist.2009-S503
- Bennett, G. J., Liu, G. K., Xiao, W. H., Jin, H. W., and Siau, C. (2011). Terminal arbor degeneration – a novel lesion produced by the antineoplastic agent paclitaxel. *Eur. J. Neurosci.* 33, 1667–1676. doi: 10.1111/j.1460-9568.2011.07652.x
- Bergstresser, P. R., and Taylor, J. R. (1977). Epidermal 'turnover time'—a new examination. *Br. J. Dermatol.* 96, 503–506. doi: 10.1111/j.1365-2133.1977.tb07152.x
- Bianchi, G., Vitali, G., Caraceni, A., Ravaglia, S., Capri, G., Cundari, S., et al. (2005). Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. *Eur. J. Cancer* 41, 1746–1750. doi: 10.1016/j.ejca.2005.04.028
- Boland, B. A., Sherry, V., and Polomano, R. C. (2010). Chemotherapy-induced peripheral neuropathy in cancer survivors. *Oncol. Nurse Edn.* 24, 33–38, 42–43.
- Boyette-Davis, J., and Dougherty, P. M. (2011). Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline. *Exp. Neurol.* 229, 353–357. doi: 10.1016/j.expneurol.2011.02.019
- Boyette-Davis, J., Xin, W., Zhang, H., and Dougherty, P. M. (2011). Intraepidermal nerve fiber loss corresponds to the development of Taxol-induced hyperalgesia and can be prevented by treatment with minocycline. *Pain* 152, 308–313. doi: 10.1016/j.pain.2010.10.030
- Breathnach, A. S. (1977). Electron microscopy of cutaneous nerves and receptors. *J. Invest. Dermatol.* 69, 8–26. doi: 10.1111/1523-1747.ep12497857
- Brederson, J. D., Joshi, S. K., Browman, K. E., Mikusa, J., Zhong, C., Gauvin, D., et al. (2012). PARP inhibitors attenuate chemotherapy-induced painful neuropathy. *J. Peripher. Nerv. Syst.* 17, 324–330. doi: 10.1111/j.1529-8027.2012.00413.x
- Broyl, A., Corthals, S. L., Jongen, J. L. M., van der Holt, B., Kuiper, R., de Knecht, Y., et al. (2010). Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. *Lancet Oncol.* 11, 1057–1065. doi: 10.1016/S1470-2045(10)70206-0
- Bruna, J., Udina, E., Alé, A., Vilches, J. J., Vynckier, A., Monbaliu, J., et al. (2010). Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. *Exp. Neurol.* 223, 599–608. doi: 10.1016/j.expneurol.2010.02.006
- Bujalska, M., and Makulska-Nowak, H. (2009). Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model. *Neuro Endocrinol. Lett.* 30, 144–152.
- Burakgazi, A. Z., Messersmith, W., Vaidya, D., Hauer, P., Hoke, A., and Polydefkis, M. (2011). Longitudinal assessment of oxaliplatin-induced neuropathy. *Neurology* 77, 980–986. doi: 10.1212/WNL.0b013e31822cfc59
- Burton, A. W., Fanciullo, G. J., Beasley, R. D., and Fisch, M. J. (2007). Chronic pain in the cancer survivor: a new frontier. *Pain Med.* 8, 189–198. doi: 10.1111/j.1526-4637.2006.00220.x
- Carozzi, V. A., Canta, A., Oggioni, N., Sala, B., Chiorazzi, A., Merelli, C., et al. (2010a). Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. *Exp. Neurol.* 226, 301–309. doi: 10.1016/j.expneurol.2010.09.004
- Carozzi, V. A., Chiorazzi, A., Canta, A., Lapidus, R. G., Slusher, B. S., Wozniak, K. M., et al. (2010b). Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. *Neurotox. Res.* 17, 380–391. doi: 10.1007/s12640-009-9114-1
- Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A. M., et al. (2002). Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. *J. Clin. Oncol.* 20, 3478–3483. doi: 10.1200/JCO.2002.07.061
- Cata, J. P., Weng, H. R., Burton, A. W., Villareal, H., Giralt, S., and Dougherty, P. M. (2007). Quantitative sensory findings in patients with bortezomib-induced pain. *J. Pain* 8, 296–306. doi: 10.1016/j.jpain.2006.09.014
- Cata, J. P., Weng, H. R., and Dougherty, P. M. (2008). Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy. *Brain Res.* 1230, 91–98. doi: 10.1016/j.brainres.2008.07.022
- Cata, J. P., Weng, H. R., Lee, B. N., Reuben, J. M., and Dougherty, P. M. (2006). Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. *Minerva Anestesiol.* 72, 151–169.
- Cavaletti, G., Bogliun, G., Marzorati, L., Zincone, A., Piatti, M., Colombo, N., et al. (2004). Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. *Ann. Oncol.* 15, 1439–1442. doi: 10.1093/annonc/mdh348
- Cavaletti, G., Gilardini, A., Canta, A., Rigamonti, L., Rodriguez-Menendez, V., Ceresa, C., et al. (2007). Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. *Exp. Neurol.* 204, 317–325. doi: 10.1016/j.expneurol.2006.11.010
- Cavaletti, G., and Marmiroli, P. (2010). Chemotherapy-induced peripheral neurotoxicity. *Nat. Rev. Neurol.* 6, 657–666. doi: 10.1038/nrneurol.2010.160
- Cavaletti, G., Pezzoni, G., Pisano, C., Oggioni, N., Sala, F., Zoia, C., et al. (2002). Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor. *Neurosci. Lett.* 322, 103–106. doi: 10.1016/S0304-3940(02)00091-5
- Cavaletti, G., Tredici, G., Braga, M., and Tazzari, S. (1995). Experimental peripheral neuropathy induced in adult-rats by repeated intraperitoneal administration of taxol. *Exp. Neurol.* 133, 64–72. doi: 10.1006/exnr.1995.1008
- Ceresa, C., and Cavaletti, G. (2011). Drug transporters in chemotherapy induced peripheral neurotoxicity: current knowledge and clinical implications. *Curr. Med. Chem.* 18, 329–341. doi: 10.2174/092986711794839160
- Chen, H., and Chan, D. C. (2006). Critical dependence of neurons on mitochondrial dynamics. *Curr. Opin. Cell Biol.* 18, 453–459. doi: 10.1016/j.ceb.2006.06.004
- Clapham, D. E. (2003). TRP channels as cellular sensors. *Nature* 426, 517–524. doi: 10.1038/nature02196
- Colombo, N., Bini, S., Miceli, D., Bogliun, G., Marzorati, L., Cavaletti, G., et al. (1995). Weekly cisplatin+/-glutathione in relapsed ovarian-carcinoma. *Int. J. Gynecol. Cancer* 5, 81–86. doi: 10.1046/j.1525-1438.1995.05020081.x
- Costa, R., Motta, E. M., Dutra, R. C., Manjavachi, M. N., Bento, A. F., Malinsky, F. R., et al. (2011). Anti-nociceptive effect of kinin B-1 and B-2 receptor antagonists on peripheral neuropathy induced by paclitaxel in mice. *Br. J. Pharmacol.* 164, 681–693. doi: 10.1111/j.1476-5381.2011.01408.x
- Croteau, D. L., Stierum, R. H., and Bohr, V. A. (1999). Mitochondrial DNA repair pathways. *Mutat. Res. DNA Repair* 434, 137–148. doi: 10.1016/S0921-8777(99)00025-7
- Deng, L. T., Guindon, J., Vemuri, V. K., Thakur, G. A., White, F. A., Makriyannis, A., et al. (2012). The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. *Mol. Pain* 8, 1–12. doi: 10.1186/1744-8069-1188-1171
- Descoeur, J., Pereira, V., Pizzoccaro, A., Francois, A., Ling, B., Maffre, V., et al. (2011). Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. *Embo. Mol. Med.* 3, 266–278. doi: 10.1002/emmm.201100134
- Devigili, G., Tugnoli, V., Penza, P., Camozzi, F., Lombardi, R., Melli, G., et al. (2008). The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. *Brain* 131, 1912–1925. doi: 10.1093/brain/awn093

- Di Cesare Mannelli, L., Zanardelli, M., Failli, P., and Ghelardini, C. (2012). Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. protective effect of silibinin. *J. Pain* 13, 276–284. doi: 10.1016/j.jpain.2011.11.009
- Di Marzo, V., Blumberg, P. M., and Szallasi, A. (2002). Endovanilloid signaling in pain. *Curr. Opin. Neurobiol.* 12, 372–379. doi: 10.1016/S0959-4388(02)00340-9
- Dougherty, P. M., Cata, J. P., Cordella, J. V., Burton, A., and Weng, H.-R. (2004). Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. *Pain* 109, 132–142. doi: 10.1016/j.pain.2004.01.021
- Doyle, T., Chen, Z., Muscoli, C., Bryant, L., Esposito, E., Cuzzocrea, S., et al. (2012). Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain. *J. Neurosci.* 32, 6149–6160. doi: 10.1523/JNEUROSCI.6343-11.2012
- Farquhar-Smith, P. (2011). Chemotherapy-induced neuropathic pain. *Curr. Opin. Support Palliat. Care* 5, 1–7. doi: 10.1097/SPC.0b013e328342f9cc
- Fidanboyu, M., Griffiths, L. A., and Flatters, S. J. L. (2011). Global inhibition of reactive oxygen species (ROS) inhibits paclitaxel-induced painful peripheral neuropathy. *PLoS ONE* 6:e25212. doi: 10.1371/journal.pone.0025212
- Fischer, S. J., McDonald, E. S., Gross, L., and Windebank, A. J. (2001). Alterations in cell cycle regulation underlie cisplatin induced apoptosis of dorsal root ganglion neurons *in vivo*. *Neurobiol. Dis.* 8, 1027–1035. doi: 10.1006/nbdi.2001.0426
- Flatters, S. J. L., and Bennett, G. J. (2004). Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. *Pain* 109, 150–161. doi: 10.1016/j.pain.2004.01.029
- Flatters, S. J. L., and Bennett, G. J. (2006). Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. *Pain* 122, 245–257. doi: 10.1016/j.pain.2006.01.037
- Flatters, S. J. L., Xiao, W. H., and Bennett, G. J. (2006). Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. *Neurosci. Lett.* 397, 219–223. doi: 10.1016/j.neulet.2005.12.013
- Florea, A.-M., and Büsselberg, D. (2011). Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. *Cancers* 3, 1351–1371. doi: 10.3390/cancers3011351
- Garcia, J. M., Cata, J. P., Dougherty, P. M., and Smith, R. G. (2008). Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. *Endocrinology* 149, 455–460. doi: 10.1210/en.2007-0828
- Gedlicka, C., Kornek, G. V., Schmid, K., and Scheithauer, W. (2003). Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid. *Ann. Oncol.* 14, 339–340. doi: 10.1093/annonc/mdg051
- Gedlicka, C., Scheithauer, W., Schull, B., and Kornek, G. V. (2002). Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. *J. Clin. Oncol.* 20, 3359–3361. doi: 10.1200/JCO.2002.99.502
- Ghirardi, O., Vertechy, M., Vesci, L., Canta, A., Nicolini, G., Galbiati, S., et al. (2005). Chemotherapy-induced allodynia: neuroprotective effect of acetyl-L-carnitine. *In Vivo* 19, 631–637.
- Giannocaro, M. P., Donadio, V., Gomis Perez, C., Borsini, W., Di Stasi, V., and Liguori, R. (2011). Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study. *Neurol. Sci.* 32, 361–363. doi: 10.1007/s10072-010-0475-2
- Gilardini, A., Avila, R. L., Oggioni, N., Rodriguez-Menendez, V., Bossi, M., Canta, A., et al. (2012). Myelin structure is unaltered in chemotherapy-induced peripheral neuropathy. *Neurotoxicology* 33, 1–7. doi: 10.1016/j.neuro.2011.10.010
- Gilchrist, L. (2012). Chemotherapy-induced peripheral neuropathy in pediatric cancer patients. *Semin. Pediatr. Neurol.* 19, 9–17. doi: 10.1016/j.spen.2012.02.011
- Goel, S., Goldberg, G. L., Kuo, D. Y., Muggia, F., Arezzo, J., and Mani, S. (2008). Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone. *Ann. Oncol.* 19, 2048–2052. doi: 10.1093/annonc/mdn420
- Goswami, C. (2012). TRPV1-tubulin complex: involvement of membrane tubulin in the regulation of chemotherapy-induced peripheral neuropathy. *J. Neurochem.* 123, 1–13. doi: 10.1111/j.1471-4159.2012.07892.x
- Gregg, R. W., Molepo, J. M., Monpetit, V. J. A., Mikael, N. Z., Redmond, D., Gadia, M., et al. (1992). Cisplatin neurotoxicity—the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphological evidence of toxicity. *J. Clin. Oncol.* 10, 795–803.
- Grisold, W., Oberndorfer, S., and Windebank, A. J. (2012). Chemotherapy and Polyneuropathies. *Eur. Assoc. NeuroOncol. Mag.* 2, 25–36.
- Gutiérrez-Gutiérrez, G., Sereno, M., Miralles, A., Casado-Sáenz, E., and Gutiérrez-Rivas, E. (2010). Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. *Clin. Transl. Oncol.* 12, 81–91. doi: 10.1007/S12094-010-0474-z
- Hansen, N., Uceyler, N., Palm, F., Zelenka, M., Biko, L., Lesch, K. P., et al. (2011). Serotonin transporter deficiency protects mice from mechanical allodynia and heat hyperalgesia in vincristine neuropathy. *Neurosci. Lett.* 495, 93–97. doi: 10.1016/j.neulet.2011.03.035
- Herrmann, D. N., Griffin, J. W., Hauer, P., Cornblath, D. R., and McArthur, J. C. (1999). Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies. *Neurology* 53, 1634–1640. doi: 10.1212/WNL.53.8.1634
- Hershman, D. L., Fehrenbacher, L., Wade, R. J. L., Wong, S.-F., Hortobagyi, G. N., Meyskens, F. L., et al. (2013). Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. *J. Clin. Oncol.* 31, 2627. doi: 10.1200/JCO.2012.44.8738
- Hershman, D. L., Weimer, L. H., Wang, A., Kranwinkel, G., Brafman, L., Fuentes, D., et al. (2011). Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. *Breast Cancer Res. Treat.* 125, 767–774. doi: 10.1007/s10549-010-1278-0
- Hilpert, F., Stahle, A., Tome, O., Burges, A., Rossner, D., Spathe, K., et al. (2005). Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group. *Support. Care Cancer* 13, 797–805. doi: 10.1007/s00520-005-0782-y
- Holland, N. R., Crawford, T. O., Hauer, P., Cornblath, D. R., Griffin, J. W., and McArthur, J. C. (1998). Small-fiber sensory neuropathies: clinical course and neuropathology of idiopathic cases. *Ann. Neurol.* 44, 47–59. doi: 10.1002/ana.410440111
- Hong, S. S., and Wiley, J. W. (2005). Early painful diabetic neuropathy is associated with differential changes in the expression and function of vanilloid receptor 1. *J. Biol. Chem.* 280, 618–627.
- Hori, K., Ozaki, N., Suzuki, S., and Sugiura, Y. (2010). Upregulations of P2X(3) and ASIC3 involve in hyperalgesia induced by cisplatin administration in rats. *Pain* 149, 393–405. doi: 10.1016/j.pain.2010.03.005
- Hoy, S. M. (2013). Subcutaneous bortezomib: in multiple myeloma. *Drugs* 73, 45–54. doi: 10.1007/s40265-013-0006-6
- Ja'afar, F. M. H., Hamdan, F. B., and Mohammed, F. H. (2006). Vincristine-induced neuropathy in rat: electrophysiological and histological study. *Exp. Brain Res.* 173, 334–345. doi: 10.1007/s00221-006-0499-2
- Jaggi, A. S., and Singh, N. (2012). Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. *Toxicology* 291, 1–9. doi: 10.1016/j.tox.2011.10.019
- Jamieson, S. M. F., Liu, J. J., Connor, B., Dragnow, M., and McKeage, M. J. (2007). Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel. *Neurotoxicology* 28, 1092–1098. doi: 10.1016/j.neuro.2007.04.009
- Janes, K., Doyle, T., Bryant, L., Esposito, E., Cuzzocrea, S., Rye, J., et al. (2013). Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase. *Pain* 154, 2432–2440. doi: 10.1016/j.pain.2013.07.032
- Ji, R. R., Samad, T. A., Jin, S. X., Schmoll, R., and Woolf, C. J. (2002). p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. *Neuron* 36, 57–68. doi: 10.1016/S0896-6273(02)00908-X
- Jimenez-Andrade, J. M., Peters, C. M., Mejia, N. A., Ghilardi, J. R., Kuskowski, M. A., and Mantyh, P. W. (2006). Sensory neurons and their supporting cells located in the trigeminal, thoracic and lumbar ganglia differentially express markers of injury following intravenous administration of paclitaxel in the rat. *Neurosci. Lett.* 405, 62–67. doi: 10.1016/j.neulet.2006.06.043
- Jin, H. W., Flatters, S. J. L., Xiao, W. H., Mulhem, H. L., and Bennett, G. J. (2008). Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. *Exp. Neurol.* 210, 229–237. doi: 10.1016/j.expneurol.2007.11.001

- Kagiava, A., Kosmidis, E. K., and Theophilidis, G. (2013). Oxaliplatin-induced hyperexcitation of rat sciatic nerve fibers: an intra-axonal study. *Anticancer Agent. Med. Chem.* 13, 373–379. doi: 10.2174/1871520611313020023
- Kamei, J., Tamura, N., and Saitoh, A. (2005). Possible involvement of the spinal nitric oxide/cGMP pathway in vincristine-induced painful neuropathy in mice. *Pain* 117, 112–120. doi: 10.1016/j.pain.2005.05.026
- Kamei, J., Zushida, K., Morita, K., Sasaki, M., and Tanaka, S. (2001). Role of vanilloid VR1 receptor in thermal allodynia and hyperalgesia in diabetic mice. *Eur. J. Pharmacol.* 422, 83–86. doi: 10.1016/S0014-2999(01)01059-7
- Kanat, O., Evrensel, T., Baran, I., Coskun, H., Zarifoglu, M., Turan, O. F., et al. (2003). Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study. *Med. Oncol.* 20, 237–245. doi: 10.1385/MO:20:3:237
- Kanavos, P. (2006). The rising burden of cancer in the developing world. *Ann. Oncol.* 17, 15–23. doi: 10.1093/annonc/mdl983
- Kaur, G., Jaggi, A. S., and Singh, N. (2010). Exploring the potential effect of *Ocimum sanctum* in vincristine-induced neuropathic pain in rats. *J. Brachial. Plex. Peripher. Nerve Inj.* 5:3. doi: 10.1186/1749-7221-5-3
- Kidd, J. F., Pilkington, M. F., Schell, M. J., Fogarty, K. E., Skepper, J. N., Taylor, C. W., et al. (2002). Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. *J. Biol. Chem.* 277, 6504–6510. doi: 10.1074/jbc.M106802200
- Kim, H. K., Zhang, Y. P., Gwak, Y. S., and Abdi, S. (2010). Phenyl N-tert-butyl nitron, a free radical scavenger, reduces mechanical allodynia in chemotherapy-induced neuropathic pain in rats. *Anesthesiology* 112, 432–439. doi: 10.1097/ALN.0b013e3181ca31bd
- Kishi, M., Tanabe, J., Schmelzer, J. D., and Low, P. A. (2002). Morphometry of dorsal root ganglion in chronic experimental diabetic neuropathy. *Diabetes* 51, 819–824. doi: 10.2337/diabetes.51.3.819
- Kocer, B., Sucak, G., Kuruoglu, R., Aki, Z., Haznedar, R., and Erdogmus, N. I. (2009). Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy. *Acta Neurol. Belg.* 109, 120–126.
- Kurniali, P. C., Luo, L. G., and Weitberg, A. B. (2010). Role of calcium/magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients. *Oncology* 24, 289–292.
- Landowski, T. H., Megli, C. J., Nullmeyer, K. D., Lynch, R. M., and Dorr, R. T. (2005). Mitochondrial-mediated dysregulation of Ca<sup>2+</sup> is a critical determinant of Velcade (PS-341/Bortezomib) cytotoxicity in myeloma cell lines. *Cancer Res.* 65, 3828–3836. doi: 10.1158/0008-5472.CAN-04-3684
- Lauria, G., Morbin, M., Lombardi, R., Borgna, M., Mazzoleni, G., Sghirlanzoni, A., et al. (2003). Axonal swellings predict the degeneration of epidermal nerve fibers in painful neuropathies. *Neurology* 61, 631–636. doi: 10.1212/01.WNL.0000070781.92512.A4
- Lee, J., Giordano, S., and Zhang, J. (2012). Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. *Biochem. J.* 441, 523–540. doi: 10.1042/BJ20111451
- Lin, P. C., Lee, M. Y., Wang, W. S., Yen, C. C., Chao, T. C., Hsiao, L. T., et al. (2006). N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. *Support. Care Cancer* 14, 484–487. doi: 10.1007/s00520-006-0018-9
- Ling, B., Coudoré-Civiale, M., Balayssac, D., Eschalié, A., Coudoré, F., and Authier, N. (2007). Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat. *Toxicology* 234, 176–184. doi: 10.1016/j.tox.2007.02.013
- Liu, C. C., Lu, N., Cui, Y., Yang, T., Zhao, Z. Q., Xin, W. J., et al. (2010). Prevention of paclitaxel-induced allodynia by minocycline: effect on loss of peripheral nerve fibers and infiltration of macrophages in rats. *Mol. Pain* 6:76. doi: 10.1186/1744-8069-6-76
- Lomonaco, M., Milone, M., Batocchi, A. P., Padua, L., Restuccia, D., and Tonali, P. (1992). Cisplatin neuropathy: clinical course and neurophysiological findings. *J. Neurol.* 239, 199–204. doi: 10.1007/BF00839140
- Lorusso, D., Ferrandina, G., Greggi, S., Gadducci, A., Pignata, S., Tateo, S., et al. (2003). Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. *Ann. Oncol.* 14, 1086–1093. doi: 10.1093/annonc/mdg301
- Løseth, S., Stålberg, E., Jorde, R., Mellgren, S. I., Institutionen För, N., Uppsala, U., et al. (2008). Early diabetic neuropathy: thermal thresholds and intraepidermal nerve fibre density in patients with normal nerve conduction studies. *J. Neurol.* 255, 1197–1202. doi: 10.1007/s00415-008-0872-0
- Lu, P., Fan, Q. X., Wang, L. X., Wang, X., Zong, H., and Wang, R. L. (2008). Prophylactic effect of amifostine on oxaliplatin-related neurotoxicity in patients with digestive tract tumors. *Ai Zheng* 27, 1117–1120.
- Luo, Z. D., Chaplan, S. R., Higuera, E. S., Sorkin, L. S., Stauderman, K. A., Williams, M. E., et al. (2001). Upregulation of dorsal root ganglion alpha(2)delta calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. *J. Neurosci.* 21, 1868–1875.
- Maestri, A., Ceratti, A. D. P., Cundari, S., Zanna, C., Cortesi, E., and Crino, L. (2005). A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. *Tumori* 91, 135–138.
- McDonald, E. S., Randon, K. R., Knight, A., and Windebank, A. J. (2005). Cisplatin preferentially binds to DNA in dorsal root ganglion neurons *in vitro* and *in vivo*: a potential mechanism for neurotoxicity. *Neurobiol. Dis.* 18, 305–313. doi: 10.1016/j.nbd.2004.09.013
- Melli, G., Taiana, M., Camozzi, F., Triolo, D., Podini, P., Quattrini, A., et al. (2008). Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. *Exp. Neurol.* 214, 276–284. doi: 10.1016/j.expneurol.2008.08.013
- Meregalli, C., Canta, A., Carozzi, V. A., Chiorazzi, A., Oggioni, N., Gilardini, A., et al. (2010). Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. *Eur. J. Pain* 14, 343–350. doi: 10.1016/j.ejpain.2009.07.001
- Meyer, L., Patte-Mensah, C., Taleb, O., and Mensah-Nyagan, A. G. (2011). Allopregnanolone prevents and suppresses oxaliplatin-evoked painful neuropathy: multi-parametric assessment and direct evidence. *Pain* 152, 170–181. doi: 10.1016/j.pain.2010.10.015
- Mihara, Y., Egashira, N., Sada, H., Kawashiri, T., Ushio, S., Yano, T., et al. (2011). Involvement of spinal NR2B-containing NMDA receptors in oxaliplatin-induced mechanical allodynia in rats. *Mol. Pain* 7, 1–7. doi: 10.1186/1744-8069-7-8
- Milla, P., Airoldi, M., Weber, G., Drescher, A., Jaehde, U., and Cattel, L. (2009). Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. *Anti-Cancer Drugs* 20, 396–402. doi: 10.1097/CAD.0b013e32832a2dc1
- Mimura, Y., Kato, H., Eguchi, K., and Ogawa, T. (2000). Schedule dependency of paclitaxel-induced neuropathy in mice: a morphological study. *Neurotoxicology* 21, 513–520.
- Mir, O., Alexandre, J., Tran, A., Durand, J. P., Pons, G., Treluyer, J. M., et al. (2009). Relationship between GSTP1 Ile105Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. *Ann. Oncol.* 20, 736–740. doi: 10.1093/annonc/mdn698
- Mironov, S. L. (2007). ADP regulates movements of mitochondria in neurons. *Biophysical J.* 92, 2944–2952. doi: 10.1529/biophysj.106.092981
- Mo, M., Erdelyi, I., Szigeti-Buck, K., Benbow, J. H., and Ehrlich, B. E. (2012). Prevention of paclitaxel-induced peripheral neuropathy by lithium pretreatment. *FASEB J.* 26, 4696–4709. doi: 10.1096/fj.12-214643
- Moore, D. H., Donnelly, J., McGuire, W. P., Almadrones, L., Cella, D. F., Herzog, T. J., et al. (2003). Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. *J. Clinical Oncol.* 21, 4207–4213. doi: 10.1200/JCO.2003.02.086
- Muthuraman, A., Jaggi, A. S., Singh, N., and Singh, D. (2008). Ameliorative effects of amiloride and pralidoxime in chronic constriction injury and vincristine induced painful neuropathy in rats. *Eur. J. Pharmacol.* 587, 104–111. doi: 10.1016/j.ejphar.2008.03.042
- Nahman-Averbuch, H., Yarnitsky, D., Granovsky, Y., Sprecher, E., Steiner, M., Tzushina, T., et al. (2011). Pronociceptive pain modulation in patients with painful chemotherapy-induced polyneuropathy. *J. Pain Symptom Manage.* 42, 229–238. doi: 10.1016/j.jpainsymman.2010.10.268
- Nakashima, T., Kiba, T., Ogawa, Y., Hosokawa, A., Shintani, H., Okada, Y., et al. (2012). A case of paclitaxel-induced peripheral neuropathy successfully treated with pregabalin. *Gan To Kagaku Ryoho* 39, 1443–1445.
- Nasu, S., Misawa, S., Nakaseko, C., Shibuya, K., Isole, S., Sekiguchi, Y., et al. (2013). Bortezomib-induced neuropathy: axonal membrane depolarization precedes development of neuropathy. *Clin. Neurophysiol.* doi: 10.1016/j.clinph.2013.07.014. [Epub ahead of print].

- Nguyen, V. H., and Lawrence, H. J. (2004). Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. *J. Clin. Oncol.* 22, 1767–1769. doi: 10.1200/JCO.2004.99.298
- Nieto, F. R., Cendan, C. M., Sanchez-Fernandez, C., Jose Cobos, E., Entrena, J. M., Tejada, M. A., et al. (2012). Role of sigma-1 receptors in paclitaxel-induced neuropathic pain in mice. *J. Pain* 13, 1107–1121. doi: 10.1016/j.jpain.2012.08.006
- Norcini, M., Vivoli, E., Galeotti, N., Bianchi, E., Bartolini, A., and Ghelardini, C. (2009). Supraspinal role of protein kinase C in oxaliplatin-induced neuropathy in rat. *Pain* 146, 141–147. doi: 10.1016/j.pain.2009.07.017
- Ocean, A. J., and Vahdat, L. T. (2004). Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. *Support. Care Cancer* 12, 619–625. doi: 10.1007/s00520-004-0657-7
- Orlando, G., Pietro Lo, G., Claudio, P., Mario, V., Augusta, B., Loredana, V., et al. (2005). Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. *Anticancer Res.* 25, 2681–2687.
- Pabbidi, R. M., Yu, S. Q., Peng, S., Khardori, R., Pauza, M. E., and Premkumar, L. S. (2008). Influence of TRPV1 on diabetes-induced alterations in thermal pain sensitivity. *Mol. Pain* 4:9. doi: 10.1186/1744-8069-4-9
- Pachman, D. R., Barton, D. L., Watson, J. C., and Loprinzi, C. L. (2011). Chemotherapy-induced peripheral neuropathy: prevention and treatment. *Clin. Pharmacol. Ther.* 90, 377–387. doi: 10.1038/clpt.2011.115
- Paice, J. A. (2011). Chronic treatment-related pain in cancer survivors. *Pain* 152, S84–S89. doi: 10.1016/j.pain.2010.10.010
- Park, S. B., Lin, C. S. Y., Krishnan, A. V., Goldstein, D., Friedlander, M. L., and Kiernan, M. C. (2011). Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. *Exp. Neurol.* 227, 120–127. doi: 10.1016/j.expneurol.2010.10.002
- Pascual, D., Goicoechea, C., Burgos, E., and Martin, M. I. (2010). Antinociceptive effect of three common analgesic drugs on peripheral neuropathy induced by paclitaxel in rats. *Pharmacol. Biochem. Behav.* 95, 331–337. doi: 10.1016/j.pbb.2010.02.009
- Pastorino, J. G., Snyder, J. W., Serroni, A., Hoek, J. B., and Farber, J. L. (1993). Cyclosporine and carnitine prevent the anoxic death of cultured-hepatocytes by inhibiting the mitochondrial permeability transition. *J. Biol. Chem.* 268, 13791–13798.
- Peltier, A. C., and Russell, J. W. (2002). Recent advances in drug-induced neuropathies. *Curr. Opin. Neurol.* 15, 633–638. doi: 10.1097/00019052-200210000-00015
- Peng, P., Xi, Q. S., Xia, S., Zhuang, L., Gui, Q., Chen, Y., et al. (2012). Pregabalin attenuates docetaxel-induced neuropathy in rats. *J. Huazhong Uni. Sci. Technol. Med. Sci.* 32, 586–590. doi: 10.1007/s11596-012-1001-y
- Periquet, M. I., Mendell, J. R., Novak, V., Collins, M. P., Nagaraja, H. N., Erdem, S., et al. (1999). Painful sensory neuropathy—prospective evaluation using skin biopsy. *Neurology* 53, 1641–1647. doi: 10.1212/WNL.53.8.1641
- Persohn, E., Canta, A., Schoepfer, S., Traebert, M., Mueller, L., Ghilardini, A., et al. (2005). Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. *Eur. J. Cancer* 41, 1460–1466. doi: 10.1016/j.ejca.2005.04.006
- Peters, C. M., Jimenez-Andrade, J. M., Kuskowski, M. A., Ghilardi, J. R., and Mantyh, P. W. (2007). An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. *Brain Res.* 1168, 46–59. doi: 10.1016/j.brainres.2007.06.066
- Podratz, J. L., Knight, A. M., Ta, L. E., Staff, N. P., Gass, J. M., Genelin, K., et al. (2011). Cisplatin induced Mitochondrial DNA damage in dorsal root ganglion neurons. *Neurobiol. Dis.* 41, 661–668. doi: 10.1016/j.nbd.2010.11.017
- Polomano, R. C., Mannes, A. J., Clark, U. S., and Bennett, G. J. (2001). A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. *Pain* 94, 293–304. doi: 10.1016/S0304-3959(01)00363-3
- Postma, T. J., Vermorken, J. B., Liefing, A. J. M., Pinedo, H. M., and Heimans, J. J. (1995). Paclitaxel-induced neuropathy. *Ann. Oncol.* 6, 489–494.
- Quasthoff, S., and Hartung, H. P. (2002). Chemotherapy-induced peripheral neuropathy. *J. Neurol.* 249, 9–17. doi: 10.1007/PL00007853
- Ribeiro-Da-Silva, A., Kenigsberg, R. L., and Cuello, A. C. (1991). Light and electron microscopic distribution of nerve growth factor receptor-like immunoreactivity in the skin of the rat lower lip. *Neuroscience* 43, 631–646. doi: 10.1016/0306-4522(91)90322-F
- Richardson, P. G., Xie, W., Mitsiades, C., Chanan-Khan, A. A., Lonial, S., Hassoun, H., et al. (2009). Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. *J. Clinical Oncol.* 27, 3518–3525. doi: 10.1200/JCO.2008.18.3087
- Roberts, J. A., Jenison, E. L., Kim, K., Clarke-Pearson, D., and Langleben, A. (1997). A Randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. *Gynecol. Oncol.* 67, 172–177. doi: 10.1006/gyno.1997.4832
- Roglio, I., Bianchi, R., Camozzi, F., Carozzi, V., Cervellini, I., Crippa, D., et al. (2009). Docetaxel-induced peripheral neuropathy: protective effects of dihydroprogesterone and progesterone in an experimental model. *J. PMS* 14, 36–44. doi: 10.1111/j.1529-8027.2009.00204.x
- Saha, L., Hota, D., and Chakrabarti, A. (2012). Evaluation of lercanidipine in Paclitaxel-induced neuropathic pain model in rat: a preliminary study. *Pain Res. Treat.* 2012:143579. doi: 10.1155/2012/143579
- Sahenk, Z., Barohn, R., New, P., and Mendell, J. R. (1994). Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. *Arch. Neurol.* 51, 726–729. doi: 10.1001/archneur.1994.00540190110024
- Saif, M. W., Syrigos, K., Kaley, K., and Isufi, I. (2010). Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. *Anticancer Res.* 30, 2927–2933.
- Schlegel, U. (2011). Central nervous system toxicity of chemotherapy. *Eur. Assoc. NeuroOncol. Mag.* 1, 25–29.
- Schmeichel, A. M., Schmelzer, J. D., and Low, P. A. (2003). Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. *Diabetes* 52, 165–171. doi: 10.2337/diabetes.52.1.165
- Schmidt, R. E., Dorsey, D., Parvin, C. A., Beaudet, L. N., Plurad, S. B., and Roth, K. A. (1997). Dystrophic axonal swellings develop as a function of age and diabetes in human dorsal root ganglia. *J. NeuroPathol. Exp. Neurol.* 56, 1028–1043. doi: 10.1097/00005072-199709000-00008
- Screnci, D., and McKeage, M. J. (1999). Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. *J. Inorg. Biochem.* 77, 105–110. doi: 10.1016/S0162-0134(99)00135-X
- Scuteri, A., Galimberti, A., Maggioni, D., Ravasi, M., Pasini, S., Nicolini, G., et al. (2009). Role of MAPKs in platinum-induced neuronal apoptosis. *Neurotoxicology* 30, 312–319. doi: 10.1016/j.neuro.2009.01.003
- Scuteri, A., Galimberti, A., Ravasi, M., Pasini, S., Donzelli, E., Cavaletti, G., et al. (2010). NGF protects dorsal root ganglion neurons from oxaliplatin by modulating JNK/SapK and ERK1/2. *Neurosci. Lett.* 486, 141–145. doi: 10.1016/j.neulet.2010.09.028
- Siau, C., and Bennett, G. J. (2006). Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. *Anesth. Analg.* 102, 1485–1490. doi: 10.1213/01.ane.0000204318.35194.ed
- Smith, E. M. L., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., et al. (2013). Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. *JAMA* 309, 1359–1367. doi: 10.1001/jama.2013.2813
- Smyth, J. F., Bowman, A., Perren, T., Wilkinson, P., Prescott, R. J., Quinn, K. J., et al. (1997). Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. *Ann. Oncol.* 8, 569–573. doi: 10.1023/A:1008211226339
- Sorensen, L., Molyneaux, L., and Yue, D. K. (2006). The relationship among pain, sensory loss, and small nerve fibers in diabetes. *Diabetes Care* 29, 883–887. doi: 10.2337/diacare.29.04.06.dc05-2180
- Stucky, C. L., and Lewin, G. R. (1999). Isolectin B4-positive and -negative nociceptors are functionally distinct. *J. Neurosci.* 19, 6497–6505.
- Suzukawa, K., Miura, K., Mitsushita, J., Resau, J., Hirose, K., Crystal, R., et al. (2000). Nerve growth factor-induced neuronal differentiation requires generation of Rac1-regulated reactive oxygen species. *J. Biol. Chem.* 275, 13175–13178. doi: 10.1074/jbc.275.18.13175
- Ta, L. E., Bieber, A. J., Carlton, S. M., Loprinzi, C. L., Low, P. A., and Windebank, A. J. (2010). Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. *Mol. Pain* 6:15. doi: 10.1186/1744-8069-6-15
- Ta, L. E., Espeset, L., Podratz, J., and Windebank, A. J. (2006). Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. *Neurotoxicology* 27, 992–1002. doi: 10.1016/j.neuro.2006.04.010

- Ta, L. E., Schmelzer, J. D., Bieber, A. J., Loprinzi, C. L., Sieck, G. C., Brederson, J. D., et al. (2013). A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. *PLoS ONE* 8:e54261. doi: 10.1371/journal.pone.0054161
- Tanner, K. D., Levine, J. D., and Topp, K. S. (1998). Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. *J. Comp. Neurol.* 395, 481–492. doi: 10.1002/(SICI)1096-9861(19980615)395:4<481::AID-CNE5>3.3.CO;2-T
- Tatsushima, Y., Egashira, N., Kawashiri, T., Mihara, Y., Yano, T., Mishima, K., et al. (2011). Involvement of substance P in peripheral neuropathy induced by paclitaxel but not oxaliplatin. *J. Pharmacol. Exp. Ther.* 337, 226–235. doi: 10.1124/jpet.110.175976
- Tatsushima, Y., Egashira, N., Narishige, Y., Fukui, S., Kawashiri, T., Yamauchi, Y., et al. (2013). Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy. *Biomed. Pharmacother.* 67, 39–42. doi: 10.1016/j.biopha.2012.10.006
- Topp, K. S., Tanner, K. D., and Levine, J. D. (2000). Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. *J. Comp. Neurol.* 424, 563–576. doi: 10.1002/1096-9861(20000904)424:4<563::AID-CNE1>3.3.CO;2-L
- Trevisan, G., Materazzi, S., Fusi, C., Altomare, A., Aldini, G., Lodovici, M., et al. (2013). Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade. *Cancer Res.* 73, 3120. doi: 10.1158/0008-5472.CAN-12-4370
- Tsujino, H., Kondo, E., Fukuoka, T., Dai, Y., Tokunaga, A., Miki, K., et al. (2000). Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: a novel neuronal marker of nerve injury. *Mol. Cell Neurosci.* 15, 170–182. doi: 10.1006/mcne.1999.0814
- van, D. H. R. G., Vecht, C. J., van, D. B. M. E., Elderson, A., Boogerd, W., Heimans, J. J., et al. (1990). Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. *N. Engl. J. Med.* 322, 89–94. doi: 10.1056/NEJM199001133220204
- Velasco, R., and Bruna, J. (2010). Chemotherapy-induced peripheral neuropathy: an unresolved issue. *Neurologia* 25, 116–131. doi: 10.1016/S0213-4853(10)70036-0
- Wang, H.-T., Liu, Z.-G., Yang, W., Liao, A.-J., Zhang, R., Wu, B., et al. (2011). Study on mechanism of bortezomib inducing peripheral neuropathy and the reversing effect of reduced glutathione. *Zhonghua xue ye xue za zhi* 32, 107–111.
- Wang, X.-M., Lehky, T. J., Brell, J. M., and Dorsey, S. G. (2012). Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. *Cytokine* 59, 3–9. doi: 10.1016/j.cyto.2012.03.027
- Warwick, R. A., and Hanani, M. (2013). The contribution of satellite glial cells to chemotherapy-induced neuropathic pain. *Eur. J. Pain* 17, 571–580. doi: 10.1002/j.1532-2149.2012.00219.x
- Wen, F., Zhou, Y., Wang, W., Hu, Q. C., Liu, Y. T., Zhang, P. F., et al. (2013). Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis. *Ann. Oncol.* 24, 171–178. doi: 10.1093/annonc/mds211
- Wilkes, G. (2007). Peripheral neuropathy related to chemotherapy. *Semin. Oncol. Nurs.* 23, 162–173. doi: 10.1016/j.soncn.2007.05.001
- Windebank, A. J., and Grisold, W. (2008). Chemotherapy-induced neuropathy. *J. Peripheral Nervous Sys.* 13, 27–46. doi: 10.1111/j.1529-8027.2008.00156.x
- Wolf, S., Barton, D., Kottschade, L., Grothey, A., and Loprinzi, C. (2008). Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. *Eur. J. Cancer* 44, 1507–1515. doi: 10.1016/j.ejca.2008.04.018
- Woodbury, C. J., Zwick, M., Wang, S. Y., Lawson, J. J., Caterina, M. J., Koltzenburg, M., et al. (2004). Nociceptors lacking TRPV1 and TRPV2 have normal heat responses. *J. Neurosci.* 24, 6410–6415. doi: 10.1523/JNEUROSCI.1421-04.2004
- Xiao, W., Boroujerdi, A., Bennett, G. J., and Luo, Z. D. (2007). Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. *Neuroscience* 144, 714–720. doi: 10.1016/j.neuroscience.2006.09.044
- Xiao, W. H., and Bennett, G. J. (2012). Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. *Pain* 153, 704–709. doi: 10.1016/j.pain.2011.12.011
- Xiao, W. H., Zheng, F. Y., Bennett, G. J., Bordet, T., and Pruss, R. M. (2009). Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel. *Pain* 147, 202–209. doi: 10.1016/j.pain.2009.09.006
- Xiao, W. H., Zheng, H., and Bennett, G. J. (2012). Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. *Neuroscience* 203, 194–206. doi: 10.1016/j.neuroscience.2011.12.023
- Xiao, W. H., Zheng, H., Zheng, F. Y., Nuydens, R., Meert, T. F., and Bennett, G. J. (2011). Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat. *Neuroscience* 199, 461–469. doi: 10.1016/j.neuroscience.2011.10.010
- Yoon, S. Y., Robinson, C. R., Zhang, H., and Dougherty, P. M. (2013). Spinal astrocyte gap junctions contribute to oxaliplatin-induced mechanical hypersensitivity. *J. Pain* 14, 205–214. doi: 10.1016/j.jpain.2012.11.002
- Zheng, H., Xiao, W. H., and Bennett, G. J. (2011). Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. *Exp. Neurol.* 232, 154–161. doi: 10.1016/j.expneurol.2011.08.016
- Zheng, H., Xiao, W. H., and Bennett, G. J. (2012). Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. *Exp. Neurol.* 238, 225–234. doi: 10.1016/j.expneurol.2012.08.023

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 03 October 2013; accepted: 28 November 2013; published online: 18 December 2013.

Citation: Han Y and Smith MT (2013) Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). *Front. Pharmacol.* 4:156. doi: 10.3389/fphar.2013.00156

This article was submitted to *Neuropharmacology*, a section of the journal *Frontiers in Pharmacology*.

Copyright © 2013 Han and Smith. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.